EKF Diagnostics, the global in vitro diagnostics company, announces that it has expanded into new larger manufacturing facilities at Llandough Trading Estate, Cardiff, to increase production of PrimeStore^® MTM viral transport media, a key component for the COVID-19 testing regime. The new facility is over 600 sq. metres, representing a 100% increase in manufacturing area. This enables EKF to fill 36,000 PrimeStore MTM tubes daily and meet growing UK and EU demand for this...

EKF Diagnostics, the global in vitro diagnostics company, announces that it has introduced one of the first tests to precisely measure levels of COVID-19 neutralizing antibodies in individuals. Unlike other antibody tests, the Kantaro COVID-SeroKlir SARS-CoV-2 IgG antibody test kit determines both the presence and specific quantities of human IgG antibodies to the SARS-CoV-2 virus. This enables a broad range of COVID-19 applications...

EKF Diagnostics, the global in vitro diagnostics company, announces that it has launched a PrimeStore® MTM sample collection kit. This new kit enables convenient and safe collection, transportation and handling of pathogenic samples, including COVID-19 and influenza. Two kit configurations are now available: a postal sample kit ideal for home use and a multi-pack of sample kits suitable for on-site mass sampling....

EKF Diagnostics, the global in vitro diagnostics company, announces that the novel viral transport media PrimeStore® MTM (Molecular Transport Medium) has been successfully evaluated for effective SARS-CoV-2 inactivation in a new study published by Public Health England (PHE). To work safely with live SARS-CoV-2 samples requires the use of high-containment laboratories....

EKF Diagnostics, the global in vitro diagnostics company, announces that it has added a novel viral transport media for the safe sample handling and testing of multiple infectious diseases from a single swab to its product range. PrimeStore® MTM (Molecular Transport Medium) is an FDA cleared and CE IVD marked sample collection device which deactivates viruses, including COVID-19, flu A, flu B, HIV and TB....

EKF Diagnostics, the global in vitro diagnostics company, announces it has secured new contracts for the manufacture and supply of a novel, patented sample collection device which allows COVID-19 samples to be rapidly inactivated in the collection tube, avoiding contamination and preserving RNA without need for refrigeration. To support the increase in COVID-19 testing globally, a safe and easy sample collection and transport mechanism is essential, this is provided by the PrimeStore^® MTM sample collection device....

EKF Diagnostics, the global in vitro diagnostics company, announces that it has opened a new Research & Development facility at its Cardiff, UK headquarters. The new Special Projects Laboratory will focus on developing new applications for EKF’s many point-of-care and central laboratory medical products to enable the Company to enter new market sectors, as well as providing additional diagnostics sales and regulatory support....

Incorrect capillary blood sampling is most common reason for inaccurate POC hemoglobin results. EKF Diagnostics, the global in vitro diagnostics company, has published an Educational Guide which provides a quick overview of capillary blood sampling best practice. It aims to help health care professionals understand common causes of pre-analytical errors and reduce their impact on hemoglobin results...

User defined application available on Beckman AU clinical chemistry analyzers for LiquiColor^® Procalcitonin (PCT) assay enabling quick and effective sepsis identification

EKF Diagnostics, the global in vitro diagnostics company, announces that its Stanbio Chemistry Procalcitonin (PCT) LiquiColor^® assay has been FDA cleared and validated for use on Beckman AU 480, 680 and 5800 clinical chemistry analyzers.....

EKF’s Beta-Hydroxybutyrate LiquiColor^® Assay for detection of predominant ketone body Now Available on Ortho’s VITROS^® 4600 Chemistry System and VITROS^® 5600 Integrated System.

Educational guide available for free download from EKF’s new Diabetes Portal

EKF Diagnostics, the global in vitro diagnostics company, has published a guide to ‘Diabetes and HbA1c testing’ which can be found at EKF’s new Diabetes Portal. This new educational guide draws on EKF’s expertise in the diagnosis and monitoring of diabetes and associated conditions....

EKF Quo-Test HbA1c analyzer successfully evaluated at Swansea University Diabetes Research Unit

EKF Diagnostics, the global in vitro diagnostics company, announces that a recent study has confirmed that its Quo-Test^® A1c point-of-care testing (POCT) analyzer shows comparable performance to a lab-based HPLC system for the measurement of glycated hemoglobin (HbA1c)....

EKF brings niche Stanbio Chemistry Procalcitonin LiquiColor^® assay to new markets

EKF Diagnostics, the global in vitro diagnostics company, announces that it is expanding the distribution of its Procalcitonin LiquiColor^® Test into Eastern Europe, Middle East and APAC regions. Procalcitonin (PCT) is a marker for bacterial infection and sepsis, a condition that has grown in awareness in recent years....

Quo-Test point of care HbA1c analyzer readily meets key performance criteria for diabetes patient monitoring

EKF Diagnostics, the global in vitro diagnostics company, announces that in a newly published paper its Quo-Test^® point-of-care (POC) hemoglobin A1c (HbA1c) analyzer has again been confirmed to meet International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) performance criteria....

Connectivity package for Quo-Lab™ and Quo-Test™ analyzers uses POCT1-A2 communication protocol for diabetic HbA1c testing.

EKF Diagnostics, the global in vitro diagnostics company, announces that it will be previewing a new point-of-care (POC) connectivity solution for its range of HbA1c analyzers at Medica 2016 in Düsseldorf from 14–17^th November. In Hall 3 / C70, EKF will be showcasing the new connectivity package for Quo-Test™ and Quo-Lab™ HbA1c analyzers...

Glycated Serum Protein assay provides simple, sensitive and fast alternative glycemic monitoring test

EKF Diagnostics, the global in vitro diagnostics company, announces that its newly introduced Glycated Serum Protein (GSP) LiquiColor^® diabetic biomarker test has been verified for use on the Siemens Vista chemistry analyzer. In a scientific poster published by scientists at the Memorial Healthcare System, Hollywood, USA [1], it was demonstrated that EKF’s GSP assay enhances the versatility of the Vista system for the specialized glycemic monitoring of...

Detailed hematology guide available for free download

EKF Diagnostics, the global in vitro diagnostics company, announces the publication of its new guide, “Anemia and hemoglobin testing” [1]. Available to download for free from ekfdiagnostics.com, the in-depth hematology guide provides a review of the symptoms and causes of anemia, through to methods for testing hemoglobin and hematocrit, as well as factors that may influence these measurements. Anemia is the most common...

New data paves way for adoption of sTNFR1 as a routine test for Diabetic Nephropathy management

EKF Diagnostics, the global in vitro diagnostics company, announces that new data has been presented in support of soluble Tumour Necrosis Factor Receptor 1 (sTNFR1) as a biomarker to predict progression of Diabetic Nephropathy (also referred to as Diabetic Kidney Disease). This new data [1] was recently presented at Kidney Week, the world’s premier nephrology meeting, organised by the American Society for Nephrology (ASN) and is...

Comparative study of tumor biopsy v noninvasive blood-based analyses published

EKF Diagnostics, the global in vitro diagnostics company, announces that results from a study involving EKF Molecular’s PointMan™ DNA enrichment technology have been published in Clinical Cancer Research [1], a journal of the American Association for Cancer Research which focusses on innovative clinical cancer research studies. The study comparing tumor biopsy with noninvasive blood-based analyses brings together...

Studies confirm utility of PointMan for molecular analysis of CTCs and circulating DNA in liquid biopsies

EKF Diagnostics, the global in vitro diagnostics company, announces that two research posters supporting the application of its PointMan™ DNA enrichment technology, for rapid and sensitive detection of lung cancer mutations, have been delivered at key conferences.  Both posters are available at www.ekfmolecular.com.  At the recent International Association for the Study of Lung Cancer’s 16th World Conference on Lung Cancer held in...

The new Altair™ 240 fully automated, cost-effective platform designed with Stanbio Chemistry products in mind

EKF Diagnostics, the global in vitro diagnostics company, announces the international launch of the Altair™ 240 clinical chemistry analyzer at the American Association for Clinical Chemistry’s (AACC) Annual Meeting and Clinical Lab Expo in Atlanta, Ga, 26-30 July. This new bench-top platform represents EKF Diagnostics’ first fully integrated chemistry system designed for the global market. Also on Booth #1018, EKF will highlight the latest additions to its range of...

Selah and GHS partner to pave the way for accessible, low-cost personalized medicine

EKF Diagnostics subsidiary, Selah Genomics, has announced the launch of its next generation sequencing (NGS) technology PrecisionPath™ in partnership with Greenville Health Systems (GHS), one of the leading community-based cancer institutes in the US. For the first time patients will have wider access to affordable advanced NGS testing that can help doctors determine the most effective cancer treatments based on an individual’s genetic...

EKF Diagnostics, the global diagnostics company, announces that it has introduced the Stanbio Chemistry Procalcitonin (PCT) LiquiColor^® Assay.

This new test enables the quantitative determination of PCT in serum samples, EDTA or lithium heparin plasma samples by latex enhanced immunoturbidimetric methodology. Procalcitonin is a marker for bacterial infection and sepsis and has been recognized as an important adjunct marker in the diagnosis of sepsis*. The new Stanbio Chemistry Procalcitonin (PCT) LiquiColor^® Assay is fast, accurate and convenient. The test provides...

PointMan used for non-invasive analysis for T790M mutations of EGFR

EKF Diagnostics, the global diagnostics company, announces that its PointMan™ DNA enrichment technology has been identified as an easy and useful method for non-invasively determining plasma EGFR T790M mutation status in late stage lung cancer patients. This is according to data presented at the American Association for Cancer Research (AACR) Annual Meeting 2015, April 18 - 22, 2015, Philadelphia, Pennsylvania. In a scientific poster entitled...

Selah Genomics, Greenville Health System, DecisionQ Corporation and BD working together to “democratize genetic medicine”

EKF Diagnostics subsidiary, Selah Genomics, has announced a major, four-way collaboration with Greenville Health System (GHS, South Carolina), DecisionQ Corporation (Virginia), and BD (Becton Dickinson and Company, New Jersey). Expected to last 18 months, the collaboration aims to unite classic clinical annotations with proprietary next generation sequencing (NGS) technology and artificial intelligence-based decision...

Glycated Serum Protein bridges the gap in diabetes testing in cases where HbA1c cannot be reliably measured

EKF Diagnostics, the global diagnostics company, announces that it has introduced a new diabetic biomarker test that provides a 2-3 week indicator of average blood glucose. The Stanbio Chemistry Glycated Serum Protein (GSP) LiquiColor^® test closes the information gap between daily blood glucose testing and the 2-3 month HbA1c reading. This means that GSP serves as an accurate intermediate marker of glycemia in instances where...

Supporting the ongoing clinical and commercial development of early Diabetic Kidney Disease biomarkers

EKF Diagnostics, the global diagnostics company, has entered a multi-year, collaborative relationship with Joslin Diabetes Center (“Joslin”) in support of the ongoing clinical and commercial translation of TNFR1 & 2 biomarkers. These novel biomarkers can help identify patients with Type 1 and Type 2 diabetes that are at an increased risk of developing end stage renal disease (ESRD), up to ten years in advance. The new agreement between...

EKF Diagnostics, the global diagnostics company, has introduced the DiaSpect TM point of care (POC) hemoglobin analyzer at Medica.

Research to confirm clinical utility of PointMan™ and CTC-iChip technologies for non-invasive cancer diagnosis and monitoring.

EKF Diagnostics, the global diagnostics company, announces that it has entered into a two year research collaboration with Massachusetts General Hospital (MGH), a global leader in successfully bridging innovative science with state-of-the-art clinical medicine, to develop PointMan™ assays that can effectively detect treatable cancer mutations in blood samples. The collaboration agreement has been signed following a detailed evaluation of...

EKF Diagnostics, the global diagnostics company, announces that the latest results from its collaboration with the Institute of Life Sciences at the University of Swansea, UK, have continued to confirm the effectiveness of its PointMan™ DNA enrichment technology for isolating and characterizing low-level DNA mutations in blood.

This is significant since with such sensitivity, it paves the way for the possibility of using a simple blood test to screen and diagnose different cancers, as well as monitor the efficacy of anti-cancer therapies. Following work undertaken by the Swansea-based team earlier this year, which successfully detected circulating free DNA (cfDNA) mutations from melanoma patients using PointMan, further studies were carried out on...

EKF Diagnostics, the global diagnostics company, today highlights that the lead scientist working in collaboration with its Kidney Biomarker team to develop tests for progressive Diabetic Kidney Disease (DKD) will receive the 2014 Kelly West Award in Epidemiology at the American Diabetes Association (ADA) 74^th Scientific Sessions.

Dr. Andrzej Krolewski, MD, PhD, Head of Section on Genetics and Epidemiology at the Joslin Diabetes Center and Professor of Medicine at Harvard Medical School, receives this eminent award in recognition of his significant contribution to the field of diabetes epidemiology. At the ADA 74^th Scientific Sessions (13-17^th June, 2014, San Francisco), Dr. Krolewski will also deliver the Kelly West Award lecture...

EKF Molecular Diagnostics, and GILUPI, an innovator in medical devices for in vivo isolation of rare cells directly from a patient’s blood stream, announce results from collaborative work using the GILUPI CellCollector^TM and EKF Molecular’s PointMan^TM DNA Enrichment technology.

The first results of the collaboration have successfully demonstrated the detection of gene mutations from as few as three or less cells isolated in a model in vitro system and from the blood of lung cancer patients.  PointMan DNA Enrichment was used to detect and analyse cells with known mutation status that had been collected on GILUPI CellCollectors under laboratory conditions.  The known mutations were those typically seen in...

EKF Diagnostics, the global diagnostics company, today confirms the growing weight of independent scientific evidence as validation that soluble TNF Receptors 1 and 2 are strong biomarkers of progressive Diabetic Kidney Disease (DKD).

EKF affirms that the markers can be reliably used as diagnostic tests to predict end-stage renal disease (ESRD) - one of the greatest mortality risks in diabetics - up to 10 years in advance. Since signing an exclusive license agreement for this novel kidney biomarker technology with the prestigious Joslin Diabetes Center (Boston, USA) in 2012, EKF Diagnostics has worked in partnership with Joslin and other key diabetic research centers to further...

EKF Diagnostics, the global in vitro diagnostics business, announces that it has acquired Selah Genomics, Inc. and DiaSpect Medical AB.

Sweden based DiaSpect manufactures desktop hemoglobin analyzers, whilst Selah, of South Carolina is a service provider that supplies molecular diagnostics tests for the development of personalized medicine. The integration of DiaSpect’s product line into the existing portfolio of EKF hemaglobin analyzers will enable the provision of an analyzer to meet any need....

Lactate testing with hematocrit compensation ideal for sports medical health checks

Following the recent launch of its new Lactate Scout+ analyzer incorporating hematocrit compensation, EKF Diagnostics, the global diagnostics business, is seeing an increasing interest from a broad range of users in both sports and medical science. Consequently, EKF has launched a specific product resource website (www.lactatescout.com) housing numerous guides and scientific papers on lactate testing...

Hematology testing company complements EKF’s POCT product portfolio. The UltraCrit is the first and only hematocrit/hemoglobin device to use ultrasound technology

EKF Diagnostics, the global in vitro diagnostics business, announces that it has acquired Separation Technology, Inc. (STI), the Florida based manufacturer of in vitro diagnostics devices for hematology testing.  This acquisition complements EKF’s existing offering in the hemoglobin testing market place, which includes Hemo Control (also sold as HemoPoint H2 in USA and Asia). Notably, STI’s primary instrument is the UltraCrit hematocrit measurement device which is FDA cleared for blood donor screening....

Ultra-sensitive PointMan™ enables blood sampling instead of tissue biopsies for cancer patient mutation status assessment

Point-of-care analyzer meets all standards set by independent certifying bodies

Swansea University, College of Medicine, presents scientific poster at IDF 2013

EKF Diagnostics, the global diagnostics business, announces the successful assessment of its Quo-Test and Quo-Lab point-of-care HbA1c analyzers within the College of Medicine, Swansea University. Dr Stephen Luzio, Associate Professor at the University, is giving a scientific poster presentation entitled ‘Assessment of two point-of-care analyzers for the determination of HbA1c’ at the World Diabetes Congress – International Diabetes Federation (IDF) 2013, Melbourne, Australia, 2^nd to 6^th December...

Quo-Test and Quo-Lab analyzers meet set requirements for determination of HbA1c

EKF Diagnostics, the global diagnostics business, announces the publication of a new white paper detailing the successful external evaluation of its Quo-Test and Quo-Lab glycated hemoglobin (HbA1c) analyzers - ‘Evaluation of four POCT-Systems for the measurement of HbA1c’. The aim of the study by scientists at IMCARMED GmbH was to compare four point-of-care (POCT) methods with established laboratory techniques for the determination of HbA1c, an internationally recognized biomarker of blood glucose levels for diabetes management...